All right, it's 10 a.m. on Tuesday. Then we'll have a subcommittee meeting with Monsieur Vincent, either you or Madam Brunelle, Mr. McTeague, Mr. Carrie, and Ms. Nash.
We are continuing our study pursuant to Standing Order 108(2), our overview of Canadian science and technology. We have five witnesses today, representing four organizations.
From Bioniche Life Sciences Inc., we have Ms. Susan Goebel, the E. coli project manager. From the Canadian Generic Pharmaceutical Association, we have Jim Keon, president. From Canada's Research-Based Pharmaceutical Companies (Rx and D), we will be hearing from Mr. Rob Livingston, vice-chair, federal affairs committee; and Mr. Normand Laberge, vice-president, federal government affairs and federal-provincial-territorial relations. Finally, from Trojan Technologies, we have Ms. Linda Gowman, chief technology officer.
Welcome to all of you. We will start with Ms. Goebel.